Karolina M. Górecka-Minakowska

Karolina M. Górecka-Minakowska

Auto-generated profile, based on publicly available information

Karolina M. Górecka-Minakowska

Captor Therapeutics Inc. Wrocław Poland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KGKarolina M. Gorecka
Karolina M. Gorecka
DKDorota Konopka-Postupolska
Dorota Konopka-Postupolska
JHJacek Hennig
Jacek Hennig
Rene BuchetRene Buchet
Rene Buchet
SPSlawomir Pikula
Slawomir Pikula

10 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KGKarolina Maria Górecka
Karolina Maria Górecka
MKMiroslav Krepl
Miroslav Krepl
ASAleksandra Szlachcic
Aleksandra Szlachcic
JPJarosław Poznański
Jarosław Poznański
JŠJiří Šponer
Jiří Šponer
MNMarcin Nowotny
Marcin Nowotny
Holliday junctions (HJs) are four-way DNA structures that occur in DNA repair by homologous recombination. Specialized nucleases, termed resolvases, remove (i.e., resolve) HJs. The bacterial protein RuvC is a canonical resolvase that introduces two symmetric cuts into the HJ. For complete resolution of the HJ, the two cuts need to be tightly coordinated. They are also specific for cognate DNA sequences. Using a combination of structural biology, biochemistry, and a computational approach, here we show that correct positioning of the substrate for cleavage requires conformational changes within the bound DNA. These changes involve rare high-energy states with protein-assisted base flipping that are readily accessible for the cognate DNA sequence but not for non-cognate sequences. These conformational changes and the relief of protein-induced structural tension of the DNA facilitate coordination between the two cuts. The unique DNA cleavage mechanism of RuvC demonstrates the importance of high-energy conformational states in nucleic acid readouts.

6 June 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
KGKarolina Górecka
Karolina Górecka
KSKamila Soboska
Kamila Soboska
MPMarcin Pacholczyk
Marcin Pacholczyk
Luciano PirolaLuciano Pirola
Luciano Pirola
ABAneta Balcerczyk
Aneta Balcerczyk
OXCT1 (3-oxoacid CoA-transferase 1), encoding the mitochondrial enzyme SCOT (succinyl-CoA:3-ketoacid CoA transferase), is a key enzyme in ketone body utilization. It catalyzes the reversible transfer of CoA from succinyl-CoA to acetoacetate, generating acetoacetyl-CoA, which is subsequently converted into acetyl-CoA for entry into the tricarboxylic acid (TCA) cycle and mitochondrial energy production. Although classically regarded as a metabolic enzyme, emerging evidence indicates that OXCT1 participates in broader regulatory networks. In addition to its protein-coding transcript, the OXCT1 locus produces regulatory non-coding RNAs, including circ-OXCT1 and lncRNA OXCT1-AS1, which provides additional levels of regulation, as for now reported in various types of cancer. Moreover, the review summarizes current knowledge on OXCT1 biochemical function, regulation, and tissue distribution, with emphasis on transcriptional control, post-translational modifications such as lysine succinylation and redox-dependent regulation, and integration with nutrient-sensing and stress-response pathways. By combining recent literature with bioinformatics analysis, we demonstrate that OXCT1 displays highly dynamic expression across diverse cancer types and metabolic states, consistent with a role in metabolic plasticity and disease progression. Furthermore, we discuss here the OXCT1 role in other pathological conditions including metabolic disorders, neurological disease, and cardiomyopathy, implicating both metabolic dysfunction and aberrant protein modification in disease mechanisms. Collectively, these findings establish OXCT1 as a central regulator of metabolic adaptation and a potential therapeutic target.

4 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DKDaria Kotlarek
Daria Kotlarek
KDKatarzyna Dudek
Katarzyna Dudek
BWBartosz Woźniak
Bartosz Woźniak
MPMartyna W. Pastok
Martyna W. Pastok
DSDmitrii Shishov
Dmitrii Shishov
MWMichał J. Walczak
Michał J. Walczak
The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL

3 April 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
DKDaria Kotlarek
Daria Kotlarek
KDKatarzyna Dudek
Katarzyna Dudek
BWBartosz Woźniak
Bartosz Woźniak
MPMartyna W. Pastok
Martyna W. Pastok
DSDmitrii Shishov
Dmitrii Shishov
MWMichał J. Walczak
Michał J. Walczak
The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.

14 April 2026 in ChemMedChem
Verified
Journal Article
Closed access
DKDaria Kotlarek
Daria Kotlarek
KDKatarzyna Dudek
Katarzyna Dudek
BWBartosz Woźniak
Bartosz Woźniak
MPMartyna W. Pastok
Martyna W. Pastok
DSDmitrii Shishov
Dmitrii Shishov
MWMichał J. Walczak
Michał J. Walczak